Free shipping on all orders over $ 500

Mavatrep

Cat. No. M10841
Mavatrep  Structure
Synonym:

JNJ-39439335

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Mavatrep is an orally active TRPV1 antagonist with high affinity for the hTRPV1 channel, inhibits the binding of the TRPV1 agonist to [3H]-Resiniferatoxin (Ki=6.5 nM), and has a low effect on the enzymatic activity of CYP subtypes 3A4, 1A2, and 2D6.

Chemical Information
Molecular Weight 422.45
Formula C25H21F3N2O
CAS Number 956274-94-5
Solubility (25°C) DMSO ≥ 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Prasarn Manitpisitkul, et al. Pain Rep. TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study

[2] Prasarn Manitpisitkul, et al. Clin Pharmacol Drug Dev. Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study

[3] Prasarn Manitpisitkul, et al. Clin Pharmacol Drug Dev. Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies

[4] Rolf Karlsten. Scand J Pain. Finally a promising analgesic signal in a long-awaited new class of drugs: TRPV1 antagonist mavatrep in patients with osteoarthritis (OA)

[5] Arthur J Mayorga, et al. Scand J Pain. A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis

Related TRP Channel Products
4-(Phenylazo)benzoic acid

4-(Phenyldiazenyl)benzoic acid is a photosensitive and photoswitchable TRPA1 agonist that can be used for the research of pain signaling.

Podocarpic acid

Podocarpic acid is a natural product, which acts as a novel TRPA1 activator.

Vocacapsaicin hydrochloride

Vocacapsaicin (CA-008) hydrochloride, as a prodrug of capsaicin, is the first non-opioid TRPV1 agonist. Vocacapsaicin hydrochloride provides lasting pain relief.

Vocacapsaicin

Vocacapsaicin (CA-008), a prodrug of capsaicin, is the first (first-in-class) non-opioid TRPV1 agonist. Vocacapsaicin can provide lasting pain relief.

GDC-0334

GDC-0334 is a TRPA1 antagonist for the treatment of TRPA1-mediated disease and is an oral candidate compound for the study of asthma.

  Catalog
Abmole Inhibitor Catalog




Keywords: Mavatrep , JNJ-39439335 supplier, TRP Channel, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.